Mizuho analyst Uy Ear maintains Sarepta Therapeutics (NASDAQ:SRPT) with a Buy and raises the price target from $145 to $179.
Mizuho Maintains Buy on Sarepta Therapeutics, Raises Price Target to $179
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.